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ABSTRACT 
Objective: Solid lipid nanoparticles (SLNs) of Curcuminoids were formulated and characterized in order to improve poor oral bioavailability of 
Curcumin. In vivo pharmacokinetics study in rats was conducted to demonstrate improved oral bioavailability.  
Methods: High pressure homogenization followed by ultrasonication method was adopted to formulate solid lipid nanoparticles of Curcumin. 
Compritol 888 ATO and Precirol ATO 5 were explored as solid lipids with LIPOID S 75 being used as surfactant. Freeze dried solid lipid 
nanoparticles were compared with marketed formulation of Curcumin (Adcumin®) in rat plasma using High Pressure Liquid Chromatography 
(HPLC) method using ultraviolet (UV) detector.  
Results: Particle size measurements performed on Solid lipid nanoparticles of Curcumin revealed the mean particle size of 200-300 nm for 
optimized formulations and entrapment efficiency of close to 80%. Sucrose and Dextrose were suitable cryoprotectants to prepare freeze dried 
solid lipid nanoparticles. Curcumin loaded solid lipid nanoparticles exhibited sustained release pattern during in vitro release kinetics.  
Conclusion: In vivo pharmacokinetics study in Swiss albino rats revealed that encapsulation of Curcumin into solid lipid nanoparticles increased 
oral bioavailability of Curcumin to 12 folds when compared with marketed formulation of Raw Curcumin (Adcumin®).  




Curcumin is one of the well-known natural chemopreventive 
compounds, obtained from rhizomes of Curcuma longa (turmeric) 
that has shown high efficacy and potency against many diseases. It 
consists of 3 structurally-related curcuminoids; Curcumin 
(Curcumin I, «80%), demethoxycurcumin (curcumin II, «15%) and 
bisdemethoxycurcumin (Curcumin III, «5%). It has shown 
tremendous potential as a potent antioxidant, anti-inflammatory, 
antiproliferative, antimetastatic, anti-angiogenic, anti-diabetic, 
hepatoprotective, antiatherosclerotic, anti-thrombotic and anti-
arthritic. It also enhances wound healing, inhibits human 
immunodeficiency viral replication and blunts the progression of 
various other diseases of pulmonary and cardiac origin [1]. 
However, in the scientific world it is well known for its potential to 
inhibit carcinogenesis induced by environmental carcinogens and 
other chemical agents [2]. It induces apoptosis in oncogenic cells by 
inhibiting various intracellular second messengers like NF-kB, AP-1, 
c-Jun, Jak-STAT pathway and various others [3]. However, major 
mechanisms of action of Curcumin are induction of endogenous 
antioxidants, enhanced expression of CYP1A1 enzymes and 
inhibition of IkB kinase. 
Although, Curcumin exhibited a ken of potent activities, it is a 
lipophilic compound with very low aqueous solubility [4]. Due to 
low solubility, it shows solubility-limited bioavailability which 
makes it a Biopharmaceutical Classification System (BCS) class II 
drug[4]. Various studies with Curcumin in rodents and humans have 
shown very low bioavailability with limited efficacy.  
Such low bioavailability limits its usefulness and hence its 
introduction into the clinical setting. Furthermore, the high doses 
required to achieve therapeutic concentrations in blood are often 
undesirable by the patients. In various clinical studies, daily doses 
from 8-12 g given to human volunteers were found to give very low 
plasma concentrations (<1 ug/ml) insufficient to exert any clinically 
useful pharmacological activity [5]. 
To combat this problem and to achieve therapeutic concentrations, 
various novel drug-delivery systems like microemulsions, liposomal 
vesicles, nanoparticles, phospholipid complexes were prepared [6-
8]. But their frequent dosing and complex manufacturing 
requirements limited their introduction into the clinical setting and 
an effective drug-delivery approach of such a high potential 
compound is still not available. 
Among modern drug delivery carriers solid lipid nanoparticles seemed 
to be a promising colloidal carrier system. Solid lipid nanoparticles 
made from biodegradable solid lipids exist in the submicron size range 
and can be prepared by several methods. The advantages of SLN are as 
follows: possibility of controlled drug release and drug targeting, 
protection of incorporated compound against chemical degradation, 
no biotoxicity of the carrier, avoidance of organic solvent and no 
problems with respect to large scale production.  
In this study, oral bioavailability of Curcumin was improved by 
encapsulating Curcumin in to Solid lipid nanoparticles. The primary 
goal was to optimize the formulation with respect to drug to lipid 
ratio and achieving desired particle size for the freeze dried product. 
The pattern of drug release was also investigated and compared 
with raw Curcumin.  
Present study focuses on formulation of solid lipid nanoparticles 
using Compritol 888 ATO and Precirol ATO 5 as solid lipids and 
LIPOID S 75 as surfactant. LIPOID S 75 is a patented natural 
phospholipid designed by LIPOID Germany and contains Lecithin 
with approximately 70% of Phosphatidylcholine. This is the first 
study that uses LIPOID S 75 as an ingredient in solid lipid 
nanoparticles of Curcumin.  
MATERIALS AND METHODS 
Materials 
Curcumin was a gift sample from Natural Remedies, Bangalore. 
LIPOID S 75 was a kind gift sample from Lipoid Germany. Compretol 
A 888, Precirol,Glycerylmonostearate, Polysorbate 80, Poloxamer 
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188, Labrafac, Mygliol, Captexwere gift samples from Gattefosse, 
India. Dialysis polyvinylidenedifluoride (PVDF) membrane of a 
1,000,000 molecular weight cut off (MWCO) was obtained from 
Spectra/Por (Becthai, Bangkok, Thailand). Sucrose, Trehalose, 
Mannitol and Glucose were purchased from Carbosynth. HPLC grade 
methanol and acetonitrile were procured from Merck. All other 
chemicals used were of analytical grade. Ultrapure water (HPLC 
grade) was used for all the experiments. 
Preparation of curcumin loaded solid lipid nanoparticles 
Nanoparticles were prepared by high pressure homogenization 
followed by ultrasonicationtechnique. The lipid was melted at a 
temperature slightly higher than 40 °C. The drug was dissolved in 
the melted lipid with continuous stirring. This constituted the lipid 
phase. The aqueous phase was prepared by dissolving surfactant 
into purified water. Lipid phase was slowly added to an aqueous 
phase with continuous stirring. The mixture was homogenized at 
1000rpm for 30 min a Remi’s high pressure homogenizer at to yield 
a uniform suspension. The homogenized suspension was subjected 
to ultrasonication for 3 min to yield particles in the nanometer size 
range. The lipid nanoparticle dispersions were washed twice with 
deionized water. The suspension was further freeze dried to yield 
Curcuminoid loaded solid lipidnanoparticles. Finally, 2% (w/v) 
sucrose was added to the dispersion before shock-frozen in liquid 
nitrogen and lyophilization at 0.30 mmHg and −30 °C for 24 h using 
Microprocessor control freeze dryer. The lipids used for preparation 
of nanoparticles were Compritol 888 ATO and Precirol ATO 5. The 
surfactants used for the process were Lipoid S 75, Poloxamer 188, 
Tween 80 and Tween 20. All the samples/batches were prepared in 
triplicates. Lipid and surfactants were used in varying 
concentrations and optimum concentrations were finalized by 
preliminary experiments.  
Physical characterization of curcumin loaded solid lipid 
nanoparticles 
Particle size and zeta potential measurements 
Particle size and polydispersity index were determined using a 
Malvern Zetasizer Nano ZS (Malvern Instrument, UK) based on 
quasi-elastic light scattering. Briefly, 1 mg/ml of nanoparticulate 
Curcumin solution was prepared in double distilled water and 
sonicated for 30 s in an ice bath. Size measurements were performed 
in triplicates following the dilution (100 ml diluted to 1 ml) of the 
NPs suspension in MilliQ water at 25 ºC. Zeta potential was 
measured in the same instrument at 25 ºC using the above protocol. 
All measurements were performed in triplicates.  
Fourier transform infrared (FTIR) spectral study 
FTIR spectra were taken in to observation (Shimadzu) to investigate 
the possible chemical interactions between the curcumin and the 
polymer matrix. Void Nanoparticles, native Curcumin, nano 
particulateCurcumin were crushed with Potassium Bromide (KBr) 
to get the pellets by applying a pressure of 300 kg/cm2. FTIR spectra 
of the above sample were obtained by averaging 32 interferograms 
with resolution of 2 cm-1 in the range of 1000-4000 cm-1
Entrapment efficiency 
.  
The percentage of drug incorporated during nanoparticle 
preparation was determined by centrifuging the drug loaded 
nanoparticles at 15,000 rpm for 15 min and separating the 
supernatant. The pellet obtained was washed twice with water and 
dissolved in acetonitrile followed by estimation of the drug in 
triplicate by a validated UV spectrophotometric method. 
In vitro quantification of curcumin 
Waters Alliance system with UV detector and analytical column 
Waters Symmetry [10] ° RP-18(150 x4.6 mm, 5μm) from Waters 
was used for curcumin quantification. Curcumin was eluted 
isocratically at a flow rate of 1 ml/min using mobile phase 
concentration of Acetonitrile: Citrate buffer pH 3.0(60:40). Injection 
volume was 20 μland retention time of curcumin was 4.8 min. Limit 
of detection and limit of quantification for curcumin was 10 and 20 
ng/ml respectively. Curcumin was determined in the concentration 
range of 0.2–10μg/ml. Peaks were measured at a wavelength of 480 
nm. The analytical method was validated according to the guidelines 
of the international conference on harmonization of technical 
requirements for registration of pharmaceuticals for human use. 
Parameters validated included precision (repeatability (intra-day) 
and intermediate precision (inter day)) and accuracy. Both the intra-
and inter-day relative standard deviations (RSD) of QC standards 
were less than 3% over the selected range. A good accuracy of the 
method was verified with recovery values of 98–101%.` 
In vitro release kinetics 
The release of drug from nanoparticulateCurcumin (Cu-SLN) was 
carried out by dissolving 100 mg of nanoparticles in 15 ml Phosphate 
buffer solution (PBS)(0.01 M, pH 7.4) and the solution was divided in 
30 eppendorf (500 \ ml each) tubes, as experiment was performed in 
triplicates. The tubes were kept in a shaker at 37 °C at 150 rpm 
(Wadegati Lab equip, India). Free curcumin is completely insoluble 
in water; therefore, at predetermined intervals of time, the solution 
was centrifuged at 3000 rpm for 10 min (Remi, Germany) to 
separate the released (pelleted) curcumin from the nanoparticulate 
curcumin. The released curcumin was re dissolved in 1 ml of 
methanol and 20 ml of this solution was injected in the HPLC to 
determine the amount of curcumin released with respect to different 
time intervals. 
Freeze drying 
In this study, freeze drying was employed as a means to impart 
stability or improve shelf life of the developed formulations. Freeze 
drying using an automated system (AdVantage, VirTis, USA) was 
adapted that was previously optimized for curcumin nanoparticles. 
To study the protective effect of various types and concentrations of 
cryoprotectants (e. g. carbohydrates), freeze-thaw cycles were 
carried out as a pre-test. 
Stability studies 
Cu-SLNs were stored in vials at 5±3 °C for 1 year, and the samples 
were withdrawn at 0, 6 and 12 months as per ICH guidelines. The 
average size, total drug content and the entrapment efficiency were 
determined at each time point. Accelerated stability studies were 
carried out at 25 °C/60% RH for 3 months.  
In vivo quantification of curcumin 
An already reported method was used for in vivo quantification of 
Curcumin. Shimadzu HPLC system with analytical column Li 
Chrospher® 100 RP-18 (250 mm×4.6 mm, 5_m) from Merck 
(Darmstadt, Germany), linked with a Nucleosil, C18 guard column 
from Macherey-Nagel (Germany) was used for in vivo curcumin 
quantification. Curcumin was eluted by a gradient flow at a rate of 1 
ml/min using mobile phase of acetonitrile, 2.8% acetic acid and 
methanol in concentrations described in table 1 and curcumin was 
eluted at 7.8 min. 17-Estradiol acetate was used as internal 
standard. Curcumin was estimated at 425 nm and 17-estradiol 
acetate at 280 nm. Limit of detection and limit of quantification for 
curcumin was 5 and 10 ng/ml respectively.  
The analytical method was validated according to the guidelines of 
the international conference on harmonization of technical 
requirements for registration of pharmaceuticals for human use. 
Parameters validated included precision (repeatability (intra-day) 
and intermediate precision (inter-day)) and accuracy. Both the 
intra-and inter-day RSD of QC standards were less than 5% over the 
selected range. A good accuracy of the method was verified with 
recovery values of 96–101%. 
Study design for in vivo pharmacokinetic studies  
For in vivo pharmacokinetic studies, male Wistar rats weighing 250–
300 g were used. The protocol was duly approved by the 
Institutional Animal Ethics Committee (IAEC) of 
KadiSarvaVishvavidyalaya, Gujarat, India. Theanimals were divided 
into two groups (n12). Group 1 (VH)was administered 50 mg/kg 
body weight (bw) of C-SLNs; and Group 2 was administered 50 
mg/kg free curcumin (Adcumin®) (C-S; solution of curcumin in 25% 
Tween 80) per orally using anoral dosing cannula. The blood 
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samples (0.5 mL) were withdrawn from retro orbital plexus under 
mild ether anesthesia and collected into heparinized 
microcentrifuge tubes (containing 20 mL of1000 IU heparin/ml of 
blood) at different time intervals. After each sampling, 1 ml of 
dextrose–normal saline was administered to prevent changes in the 
central compartment volume and electrolytes. Plasma was separated by 
centrifuging the blood samples at 4000 rpm for 10 min at 41 °C. After 
centrifugation, the plasma obtained was stored at 20 °C until analysis 
RESULTS AND DISCUSSION 
Preparation of curcumin loaded solid lipid nanoparticles 
The choice of particular solid lipid, drug to lipid ratio and 
concentration of surfactants are the driving factors for preparation 
of stable Curcuminoid loaded solid lipid nanoparticles. Screening of 
suitable lipid phase and drug to lipid ratio are two most important 
parameters. The effect of surfactant concentration and drug to lipid 
ratio was studied on characteristics of Curcuminoid loaded SLNs. 
Table 2 describes the details of experimental designs and the 
respective outcome. 
Various formulations of Curcumin loaded SLNs were designed 
varying drug to lipid ratio and concentration of surfactants. As 
described in Material and Methods, Compretol A888 and Precirol 
ATO 5 were used as solid lipid while LIPOID S 75was used as 
surfactant (Stabilizer). Particle size distribution, Drug loading and 
Entrapment efficiency were the parameters used to conclude 
suitable drug to lipid ratio and optimum surfactant concentration.
 
Table 1: Gradient for analytical method for in vivo quantification of Curcumin 
Time Acetonitrile % Acetic acid % Methanol % 
0 35 55 10 
4 45 25 30 
6 40 30 30 
8 35 55 10 
 




Curcumin  Compritol 888 
ATO (%) 
Precirol 












Cu SLNs A 0.1 - 20 5 1 73.9 0.322±0.089 38.5±1.2 
Cu SLNs B 0.5 - 20 5 1 73.5 0.289±0.014 32.7±4.9 
Cu SLNs C 1 - 20 5 1 73 0.222±0.032 70±5.3 
Cu SLNs D 0.1 20 - 5 1 73.9 0.242±0.039 56±11.2 
Cu SLNs E 0.5 20 - 5 1 73.5 0.259±0.049 41.7±0.5 
Cu SLNs F 1 20 - 5 1 73 0.289±0.085 80.1±0.9 
Cu SLNs G 0.1 - 20 8 1 70.9 0.334±0.011 70.6±4.1 
Cu SLNs H 0.5 - 20 8 1 70.5 0.482±0.020 65.6±2.3 
Cu SLNs I 1 - 20 8 1 70 0.358±0.059 68.6±6.8 
Cu SLNs J 0.1 20 - 8 1 70.9 0.526±0.043 61.1±1.1 
Cu SLNs K 0.5 20 - 8 1 70.5 0.449±0.114 65.2±1.2 
Cu SLNs L 1 20 - 8 1 70 0.305±0.144 41±3.2 
It was found that at drug to lipid ratio of 1:20, both the lipids viz. Compritol 888 ATO and Precirol ATO 5 led to solid lipid nanoparticles with highest 
entrapment efficiency and particle size within 200-300 nm.  
 
Table 3: Freeze drying studies with different cryoprotectants and particle size measurement 
Cu-SLN 
S. No.  Cryoprotectant d(0.9) before freeze drying d(0.9) after freeze drying 
1 Sucrose 0.242±0.039 0.237±0.045 
2 Dextrose 0.242±0.039 0.256±0.067 
3 Mannitol 0.242±0.039 0.382±0.021 
4 No Sugar 0.242±0.039 1.012±0.101 
 
 
Fig. 1: Raw Curcumin and Curcumin loaded solid lipid nanoparticles in dispersion form 
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Zeta potential and FTIR measurement for optimized 
formulations 
Zeta potential measured for Formulation C and F indicated high 
charge on particles that helps the formulation nanoparticles repel 
each other in order to have long term stability. Further to confirm 
encapsulation of Curcumin into nanoparticles, FTIR measurement 
was conducted for native Curcumin, nanoparticulate Curcumin and 
void nanoparticles. The broadening of peak at 3390 cm-1
In vitro release kinetics for Nanocurcumin 
indicates 
enhancement of hydrogen bonding. Marker peaks for Curcumin 
were not found in void Curcumin that indicates an encapsulation of 
Curcumin into nanoparticles.  
Freeze drying 
Evident from the literature, SLN dispersions shows an increase in 
particle size in a short period of time during the storage due to 
Ostwald ripening and hydrolysis reactions. Particle size of solid lipid 
nanoparticles is reported to cross the nanometric range within a 
week. Lyophilization offers chemical and physical stability by 
preventing Ostwald ripening and hydrolysis reactions [9]. 
 Cryoprotectants have been used to decrease SLN aggregation due to 
the stress during the process of freeze-drying. Various 
cryoprotectants were screened at the concentrations of 5 % w/v. 
Mannitol resulted into a collapsed cake which was non dispersible. 
Sucrose and dextrose worked well with Cu-SLNs. The particle size 
also remained similar before and after freeze drying. 
Solubility and stability studies for curcumin 
To confirm solubility of nano curcumin in aqueous media, we found 
that nano Curcumin resulted into a well dispersed aqueous liquid. IN 
contrast, native Curcumin is poorly wettable and poorly soluble in 
aqueous media. One of the major challenges in drug delivery of 
Curcumin is poor stability at physiological pH as well.  
In order to demonstrate stability of nanoformulations at 
physiological pH, we incubated our formulations and native 
Curcumin in PBS (pH: 7.4) and estimated concentration with time 
using HPLC method. It was observed that native Curcumin 
underwent rapid degradation and only 3% of Curcumin remained 
intact after 4 hours of incubation. However, nanoparticulate 
Curcumin was stable at the same conditions.  
In vitro release kinetics studies for Curcumin loaded SLNs exhibited 
a sustained release pattern. Sustained release was observed over a 
period of 7 days. Initial burst release can be attributed to dissociation of 
surface absorbed Curcumin into lipid matrix while sustained released 
over a period of 7 days can be attributed to release of Curcumin from 
nanoparticles. Native Curcumin was visibly insoluble in PBS and after 7 
days, only 6% drug releases were observed. 
 
 
Fig. 2: In vitro release kinetics of Curcumin loaded SLNs 
 
In vivo pharmacokinetics studies 
Curcuminoid loaded SLNs were designed in order to improve 
extremely poor bioavailability associated with Curcumin, a drug 
with tremendous therapeutic potential. Plasma levels of Curcumin 
after administration as SLNs were compared with those attained 
after oral administration of raw Curcumin (Adcumin®). Negligible 
plasma levels were attained after administration of raw Curcumin. 
The plasma levels were so low that they were below detection limit 
of the method for the first few time points. Encapsulation of 
Curcumin into SLNs led to 12 fold increase in bioavailability. The 
relative pharmacokinetic parameters Cmax, Tmax and Area under 
curve (AUC) are listed in table 4. 
  
Table 4: In vivo pharmacokinetics for Curcumin loaded solid lipid nanoparticles 
Formulation Cmax T(ng/ml) max AUC(h) 0-∞ Relative BA (ng-/ml-h) 
Adcumin® 35.5±10.6 2 40.8±30.5 NA 
Cu-SLNs 624.5±65.4 6 488±81.5 1196% 
 
 




Curcumin derived from the common food spice turmeric has been 
used for centuries as a remedy for many disorders as mentioned in 
the foregoing sections. Scientific research over the past decade has 
shown the compound to possess the preventive and therapeutic 
value against the wide variety of diseases. Despite its promising 
pharmacological activity, Curcumin’s low oral bioavailability has 
remained a major hurdle. Biologists, who have studied Curcumin 
extensively, are puzzled by its bioavailability problems. History of 
use for over 100 years, on the other hand has prevented 
pharmaceutical scientists, who specialize in addressing this issue, 
from this pursuit. After the research for Curcumin hit a roadblock 
due to the poor biopharmaceutical properties, most importantly the 
low solubility and poor intestinal permeability, it has become a 
molecule of interest to the drug delivery scientists. Considering the 
potential of nanoparticles as oral drug delivery system, the present 
investigation involved development and characterization of 
polymeric Curcumin nanoparticles with a view to improve its oral 
bioavailability.  
Curcumin loaded SLNs were prepared by hot homogenization 
followed by ultrasonication method. The process yielded SLNs with 
200-300 nm with higher entrapment efficiency. Both the solid lipids 
selected for the study Compritol 888 ATO and Precirol ATO 5 yielded 
SLNs with the desired particle size with high entrapment efficiency. 
For the purpose of further in vivo studies and characterization, SLNs 
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formulated with Compritol 888 ATO were selected. The SLNs were 
also subjected to in vitro release studies. The selection of dissolution 
medium for such poorly soluble drugs has always been a challenge. 
For the present study, Phosphate buffer pH 7.4 was selected as the 
dissolution medium. The results of the in vitro release studies not 
only exhibited improved solubility but also sustained release pattern 
for Curcumin from the nanoparticles. The release of drug from 
nanoparticles was affected by several parameters which include 
physiochemical properties of drug and polymer, size of particles, 
type of surfactant/stabilizer used for particle preparation, amount of 
drug loading and nature of release medium and the study may not 
provide true insight considering the difficulties involved in 
establishing IVIV.  
Apart from solubility and permeability, stability of Curcumin also 
presents a major challenge in the formulation of dosage forms. 
Curcumin is highly sensitive to light and oxidation. It is well known 
that a lyoprotectant is necessary to decrease nanoparticle 
aggregation during the lyophilization process. It was demonstrated 
that encapsulation of Curcumin into SLNs also improved stability of 
Curcumin. Compared to native Curcumin, which got degraded by 
97% in only 3 h, freeze dried Curcumin loaded SLNs were stable for 
6 months at 2-8ºC. Thus freeze drying of Cu-SLNs with sucrose or 
dextrose as cryoprotectants, improved long term stability of 
Curcumin. These findings are in agreement with the results of other 
researchers suggesting that the transformation of SLNs into a dry 
powder can prevent the aggregation of nanoparticles and improve 
the stability of light and oxygen sensitive substances [9]. 
In vivo pharmacokinetics studies in Rat plasma revealed that 
encapsulation of Curcumin into SLNs increased relative bioavailability 
of Curcumin by 12 folds. Marketed capsule formulation of Curcumin 
(Adcumin) was selected for comparison. It was found that native 
Curcumin showed negligible plasma levels when administered 
through oral route. While nanoparticulate Curcumin led to sustained 
release of Curcumin into plasma making it bioavailable. Raw Curcumin 
through oral route thus may only be used for ailments that require 
local action while nanoparticulate Curcumin may also be useful for 
malignancies that require systemic action.  
Past research to improve Curcumin bioavailability has shown that 
bioavailability of Curcumin can be increased by combining it with 
Piperine, a well-known inhibitor of hepatic and intestinal 
glucuronidation [10]. Shaikh et al. [11] prepared polymeric 
nanoparticles of Curcumin and demonstrated that nanoparticulate 
encapsulation of Curcumin improved bioavailability by 9 folds 
compared to Curcumin administered with Piperine as absorption 
enhancer. Solid lipid nanoparticles present advantages over 
polymeric nanoparticles in the way that solid lipid nanoparticles are 
more biologically accepted as they are made from biodegradable 
solid lipids and they offer higher potential for sustained release as 
depicted in the present study.  
CONCLUSION 
Curcumin loaded solid lipid nanoparticles were successfully 
formulated using high pressure homogenization followed by ultra-
sonication technique.  
The mean particle size could be achieved in the range of 200-300 nm 
with entrapment efficiency of more than 70%. The in vivo 
pharmacokinetics studies in rats have demonstrated that 
encapsulation into nano carriers can significantly improve oral 
bioavailability and stability of Curcumin. The major hurdle of 
bringing this molecule, with tremendous therapeutic potential to 
clinic is possible by means of nanotechnology and further trials in 
human volunteers need to be conducted to establish safety and 
efficacy.  
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